clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2025-103-1-13-22clinmed-1039Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESВозрастные и гендерные аспекты болезни ПаркинсонаAge and gender aspects of parkinson's diseasehttps://orcid.org/0000-0003-0632-6653ЮсуповФ. А.YusupovF. A.

Юсупов Фуркат Абдулахатович — д-р мед. наук, профессор медицинского факультета

Ош

Furkat A.Yusupov — Doctor of Medical Sciences, Professor of the Faculty of Medicine

Osh

https://orcid.org/0009-0008-6178-8678ЫдырысовИ. Т.YdyrysovI. T.

Ыдырысов Исматилла Токтосунович — д-р мед. наук, профессор медицинского факультета

Ош

Ismatilla T.Ydyrysov — Doctor of Medical Sciences, Professor of the Faculty of Medicine

Osh

https://orcid.org/0000-0001-5549-3832АбдыкадыровМ. Ш.AbdykadyrovM. Sh.

Абдыкадыров Мухаммадюсуф Шкуратович — аспирант медицинского факультета

Ош

Muhammadyusuf Sh. Abdykadyrov — postgraduate student of the medical faculty

Osh

aratingo@mail.ruhttps://orcid.org/0000-0002-8502-2203ЮсуповаТ. Ф.YusupovaT. F.

Юсупова Турсуной Фуркатовна — медицинский факультет

Ош

Tursunoy F. Yusupova — Faculty of Medicine

Osh

Ошский государственный университетКыргызстанOsh State UniversityKyrgyzstan20250805202510311322Copyright © Юсупов Ф.А., Ыдырысов И.Т., Абдыкадыров М.Ш., Юсупова Т.Ф., 20252025Юсупов Ф.А., Ыдырысов И.Т., Абдыкадыров М.Ш., Юсупова Т.Ф.Yusupov F.A., Ydyrysov I.T., Abdykadyrov M.S., Yusupova T.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/1039

Болезнь Паркинсона (БП) по-разному влияет на мужчин и женщин, обусловливая уникальные вызовы и подходы в ее лечении. У мужчин риск развития БП в два раза выше, чем у женщин, но у женщин наблюдаются более быстрое прогрессирование заболевания и более высокий уровень смертности. Кроме того, моторные и немоторные симптомы, реакция на лечение и факторы риска различаются у мужчин и женщин. Эти различия поддерживают гипотезу о том, что патогенез заболевания может включать различные механизмы у пациентов разного пола или одни и те же механизмы, проявляющиеся по-разному. В настоящем обзоре обобщены современные знания о гендерных различиях в клинических проявлениях БП, факторах риска, ответе на лечение и патофизиологических механизмах заболевания. Понимание того, как патология по-разному влияет на мужчин и женщин, может способствовать разработке индивидуализированных вмешательств и инновационных программ, отвечающих различным потребностям пациентов обоих полов, улучшая тем самым качество ухода за ними.

Parkinson’s disease (PD) affects men and women differently, creating unique challenges and approaches in its treatment. Men are twice as likely to develop PD as women, but women experience higher mortality rates and faster disease progression. Moreover, motor and non-motor symptoms, response to treatment, and risk factors differ between men and women. These differences support the hypothesis that the disease’s pathogenesis may involve different mechanisms in male and female patients, or the same mechanisms manifesting differently. This review summarizes current knowledge on gender differences in the clinical manifestations of PD, risk factors, treatment response, and the disease’s pathophysiological mechanisms. Understanding how the pathology differently affects men and women can aid in the development of individualized interventions and innovative programs to meet the varied needs of patients of both sexes, thereby improving the quality of care.

болезнь Паркинсонательца Левиглубокая стимуляция мозга (DBS)эстрогенальфасинуклеинParkinson’s diseaseLewy bodiesdeep brain stimulation (DBS)estrogenalpha-synucleinИсследование не имело спонсорской поддержки.ReferencesЮсупов Ф.А., Юлдашев А.А., Нурматов Т.А. Биомаркеры ранней диагностики болезни Паркинсона. Бюллетень науки и практики. 2024;10(7):309–323. DOI: 10.33619/2414-2948/104/33Yusupov F.А., Yuldashev A.А, Nurmatov T.А. Biomarkers of Early Diagnosis of Parkinson’s Disease. Bulletin of science and practice. 2024;10(7):309–323. (In Russian). DOI: 10.33619/2414-2948/104/33Helle J. (2014). Evidence for gender differences in cognition, emotion and quality of life in Parkinson’s disease? Aging and Disease. 2013;5(1):63–75. DOI: 10.14336/ad.2014.050063Helle J. (2014). Evidence for gender differences in cognition, emotion and quality of life in Parkinson’s disease? Aging and Disease. 2013;5(1):63–75. DOI: 10.14336/ad.2014.050063Picillo M., Erro R., Amboni M., Longo K., Vitale C., Moccia M.et al. Gender differences in non-motor symptoms in early Parkinson’s disease: A 2-years follow-up study on previously untreated patients. Parkinsonism and amp; Related Disorders, 2014;20(8):850–854. DOI: 10.1016/j.parkreldis.2014.04.023Picillo M., Erro R., Amboni M., Longo K., Vitale C., Moccia M.et al. Gender differences in non-motor symptoms in early Parkinson’s disease: A 2-years follow-up study on previously untreated patients. Parkinsonism and amp; Related Disorders, 2014;20(8):850–854. DOI: 10.1016/j.parkreldis.2014.04.023Baldereschi M., Di Carlo A., Rocca W.A., Vanni P., Maggi S., Perissinotto E., Grigoletto F., Amaducci L., & Inzitari, D. Parkinson’s disease and parkinsonism in a longitudinal study. Neurology, 2000;55(9):1358–1363. DOI: 10.1212/wnl.55.9.1358Baldereschi M., Di Carlo A., Rocca W.A., Vanni P., Maggi S., Perissinotto E., Grigoletto F., Amaducci L., & Inzitari, D. Parkinson’s disease and parkinsonism in a longitudinal study. Neurology, 2000;55(9):1358–1363. DOI: 10.1212/wnl.55.9.1358Solla P., Cannas A., Ibba F.C., Loi F., Corona M., Orofi no G., Marrosu M.G., & Marrosu F. (). Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson’s disease. Journal of the Neurological Sciences. 2012;323(1–2):33– 39. DOI: 10.1016/j.jns.2012.07.026Solla P., Cannas A., Ibba F.C., Loi F., Corona M., Orofi no G., Marrosu M.G., & Marrosu F. (). Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson’s disease. Journal of the Neurological Sciences. 2012;323(1–2):33– 39. DOI: 10.1016/j.jns.2012.07.026Dahodwala N., Shah K., He Y., Wu S. S., Schmidt P., Cubillos F., & Willis A.W. (2018). Sex disparities in access to caregiving in Parkinson disease. Neurology, 2017;90(1):e48–e54. DOI: 10.1212/wnl.0000000000004764Dahodwala N., Shah K., He Y., Wu S. S., Schmidt P., Cubillos F., & Willis A.W. (2018). Sex disparities in access to caregiving in Parkinson disease. Neurology, 2017;90(1):e48–e54. DOI: 10.1212/wnl.0000000000004764Georgiev D., Hamberg K., Hariz M., Forsgren L., Hariz G.-M. Gender differences in Parkinson’s disease: A clinical perspective. Acta Neurologica Scandinavica. 2017;136(6):570–584. Portico. DOI: 10.1111/ane.12796Georgiev D., Hamberg K., Hariz M., Forsgren L., Hariz G.-M. Gender differences in Parkinson’s disease: A clinical perspective. Acta Neurologica Scandinavica. 2017;136(6):570–584. Portico. DOI: 10.1111/ane.12796Willis A.W., Schootman M., Evanoff B.A., Perlmutter J.S., Racette B.A. Neurologist care in Parkinson disease. Neurology. 2011;77(9):851–857. DOI: 10.1212/wnl.0b013e31822c9123Willis A.W., Schootman M., Evanoff B.A., Perlmutter J.S., Racette B.A. Neurologist care in Parkinson disease. Neurology. 2011;77(9):851–857. DOI: 10.1212/wnl.0b013e31822c9123Richter D., Bartig D., Muhlack S., Hartelt E., Scherbaum R., Katsanos A.H. et al. Dynamics of Parkinson’s disease multimodal complex treatment in germany from 2010–2016: patient characteristics, access to treatment, and formation of regional centers. Cells. 2019;8(2):151. DOI: 10.3390/cells8020151Richter D., Bartig D., Muhlack S., Hartelt E., Scherbaum R., Katsanos A.H. et al. Dynamics of Parkinson’s disease multimodal complex treatment in germany from 2010–2016: patient characteristics, access to treatment, and formation of regional centers. Cells. 2019;8(2):151. DOI: 10.3390/cells8020151Wirtz V.J. Priority medicines for Europe and the World: setting a public-health-based medicines development agenda. Journal of Pharmaceutical Policy and Practice. 2015;8(S1). DOI: 10.1186/2052-3211-8-s1-k4Wirtz V.J. Priority medicines for Europe and the World: setting a public-health-based medicines development agenda. Journal of Pharmaceutical Policy and Practice. 2015;8(S1). DOI: 10.1186/2052-3211-8-s1-k4Hirsch L., Jette N., Frolkis A., Steeves T., Pringsheim T. The Incidence of Parkinson’s Disease: A Systematic Review and MetaAnalysis. Neuroepidemiology. 2016;46(4):292–300. Portico. DOI: 10.1159/000445751Hirsch L., Jette N., Frolkis A., Steeves T., Pringsheim T. The Incidence of Parkinson’s Disease: A Systematic Review and MetaAnalysis. Neuroepidemiology. 2016;46(4):292–300. Portico. DOI: 10.1159/000445751Savica R., Grossardt B.R., Rocca W.A., Bower J.H. Parkinson disease with and without Dementia: A prevalence study and future projections. Movement Disorders. 2018;33(4):537–543. Portico. DOI: 10.1002/mds.27277Savica R., Grossardt B.R., Rocca W.A., Bower J.H. Parkinson disease with and without Dementia: A prevalence study and future projections. Movement Disorders. 2018;33(4):537–543. Portico. DOI: 10.1002/mds.27277Larsson V., Torisson G., Londos E. Relative survival in patients with dementia with Lewy bodies and Parkinson’s disease dementia. PLOS ONE. 2018;13(8):e0202044. DOI: 10.1371/journal.pone.0202044Larsson V., Torisson G., Londos E. Relative survival in patients with dementia with Lewy bodies and Parkinson’s disease dementia. PLOS ONE. 2018;13(8):e0202044. DOI: 10.1371/journal.pone.0202044Park K., Oeda T., Kohsaka M., Tomita S., Umemura A., & Sawada H. (). Low body mass index and life prognosis in Parkinson’s disease. Parkinsonism and Related Disorders, 2018;55:81–85. DOI: 10.1016/j.parkreldis.2018.05.011Park K., Oeda T., Kohsaka M., Tomita S., Umemura A., & Sawada H. (). Low body mass index and life prognosis in Parkinson’s disease. Parkinsonism and Related Disorders, 2018;55:81–85. DOI: 10.1016/j.parkreldis.2018.05.011Baba Y., Putzke J.D., Whaley N.R., Wszolek Z.K., & Uitti R.J. (). Gender and the Parkinson’s disease phenotype. Journal of Neurology. 2005;252(10):1201–1205. DOI: 10.1007/s00415-005-0835-7Baba Y., Putzke J.D., Whaley N.R., Wszolek Z.K., & Uitti R.J. (). Gender and the Parkinson’s disease phenotype. Journal of Neurology. 2005;252(10):1201–1205. DOI: 10.1007/s00415-005-0835-7Haaxma C.A., Bloem B.R., Borm G.F., Oyen W.J.G., Leenders K.L. et al. Gender differences in Parkinson’s disease. Journal of Neu rology, Neurosurgery and Psychiatry. 2007;78(8):819–824. DOI: 10.1136/jnnp.2006.103788Haaxma C.A., Bloem B.R., Borm G.F., Oyen W.J.G., Leenders K.L. et al. Gender differences in Parkinson’s disease. Journal of Neu rology, Neurosurgery and Psychiatry. 2007;78(8):819–824. DOI: 10.1136/jnnp.2006.103788Colombo D., Abbruzzese G., Antonini A., Barone P., Bellia G., Franconi F. et al. The “Gender Factor” in wearing‐off among patients with Parkinson’s disease: a post hoc analysis of DEEP Study. The Scientific World Journal. 2015;1. DOI: 10.1155/2015/787451Colombo D., Abbruzzese G., Antonini A., Barone P., Bellia G., Franconi F. et al. The “Gender Factor” in wearing‐off among patients with Parkinson’s disease: a post hoc analysis of DEEP Study. The Scientific World Journal. 2015;1. DOI: 10.1155/2015/787451Kim R., Lee, J., KimY., Kim A., Jang M., Kim H.-J. et al. (). Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson’s disease: An analysis of the PPMI cohort. Parkinsonism and Related Disorders. 2018;51:49–54. DOI: 10.1016/j.parkreldis.2018.02.047Kim R., Lee, J., KimY., Kim A., Jang M., Kim H.-J. et al. (). Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson’s disease: An analysis of the PPMI cohort. Parkinsonism and Related Disorders. 2018;51:49–54. DOI: 10.1016/j.parkreldis.2018.02.047Parashos S.A., Bloem B.R., Browner N.M., Giladi N., Gurevich T., Hausdorff J.M. et al. What predicts falls in Parkinson disease? Neurology Clinical Practice. 2018;8(3):214–222. DOI: 10.1212/cpj.0000000000000461Parashos S.A., Bloem B.R., Browner N.M., Giladi N., Gurevich T., Hausdorff J.M. et al. What predicts falls in Parkinson disease? Neurology Clinical Practice. 2018;8(3):214–222. DOI: 10.1212/cpj.0000000000000461Ou R., Liu H., Hou Y., Song W., Cao B., Wei Q.et al. Predictors of camptocormia in patients with Parkinson’s disease: A prospective study from southwest China. Parkinsonism & Related Disorders. 2018;52:69–75. DOI: 10.1016/j.parkreldis.2018.03.020Ou R., Liu H., Hou Y., Song W., Cao B., Wei Q.et al. Predictors of camptocormia in patients with Parkinson’s disease: A prospective study from southwest China. Parkinsonism & Related Disorders. 2018;52:69–75. DOI: 10.1016/j.parkreldis.2018.03.020Martinez-Martin P., Pecurariu C. F., Odin P., Hilten J.J., Antonini A., Rojo-Abuin J.M. et al. Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease. Journal of Neurology. 2012;259(8):1639–1647. DOI: 10.1007/s00415-011-6392-3Martinez-Martin P., Pecurariu C. F., Odin P., Hilten J.J., Antonini A., Rojo-Abuin J.M. et al. Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease. Journal of Neurology. 2012;259(8):1639–1647. DOI: 10.1007/s00415-011-6392-3Silverdale M.A., Kobylecki C., Kass-Iliyya L., Martinez-Martin P., Lawton M., Cotterill S. et al. A detailed clinical study of pain in 1957 participants with early/moderate Parkinson’s disease. Parkinsonism & Related Disorders. 2018;56:27–32. DOI: 10.1016/j.parkreldis.2018.06.001Silverdale M.A., Kobylecki C., Kass-Iliyya L., Martinez-Martin P., Lawton M., Cotterill S. et al. A detailed clinical study of pain in 1957 participants with early/moderate Parkinson’s disease. Parkinsonism & Related Disorders. 2018;56:27–32. DOI: 10.1016/j.parkreldis.2018.06.001Houser M.C., Chang J., Factor S.A., Molho E.S., Zabetian C.P., Hill‐Burns E.M.et al. Stool immune profiles evince gastrointestinal inflammation in Parkinson’s disease. Movement Disorders. 2018;33(5):793–804. Portico. DOI: 10.1002/mds.27326Houser M.C., Chang J., Factor S.A., Molho E.S., Zabetian C.P., Hill‐Burns E.M.et al. Stool immune profiles evince gastrointestinal inflammation in Parkinson’s disease. Movement Disorders. 2018;33(5):793–804. Portico. DOI: 10.1002/mds.27326Nienstedt J. C., Bihler M., Niessen A., Plaetke R., Pötter‐Nerger M., Gerloff C., Buhmann C., Pflug C. Predictive clinical factors for penetration and aspiration in Parkinson’s disease. Neurogastroenterology & Motility. 2018;31(3). DOI: 10.1111/nmo.13524Nienstedt J. C., Bihler M., Niessen A., Plaetke R., Pötter‐Nerger M., Gerloff C., Buhmann C., Pflug C. Predictive clinical factors for penetration and aspiration in Parkinson’s disease. Neurogastroenterology & Motility. 2018;31(3). DOI: 10.1111/nmo.13524Mao C.J., Xiong Y.T., Wang F., Yang Y.P., Yuan, W., Zhu C.et al. Motor subtypes and other risk factors associated with drooling in Parkinson’s disease patients. Acta Neurologica Scandinavica. 2018;137(5):509–514. DOI: 10.1111/ane.12893Mao C.J., Xiong Y.T., Wang F., Yang Y.P., Yuan, W., Zhu C.et al. Motor subtypes and other risk factors associated with drooling in Parkinson’s disease patients. Acta Neurologica Scandinavica. 2018;137(5):509–514. DOI: 10.1111/ane.12893Cholerton B., Johnson C.O., Fish B., Quinn J.F., Chung K.A., Peterson-Hiller A.L. et al. Sex differences in progression to mild cognitive impairment and dementia in Parkinson’s disease. Parkinsonism & Related Disorders. 2018;50:29–36. DOI: 10.1016/j.parkreldis.2018.02.007Cholerton B., Johnson C.O., Fish B., Quinn J.F., Chung K.A., Peterson-Hiller A.L. et al. Sex differences in progression to mild cognitive impairment and dementia in Parkinson’s disease. Parkinsonism & Related Disorders. 2018;50:29–36. DOI: 10.1016/j.parkreldis.2018.02.007Lin S.-J., Baumeister, T.R., Garg S., McKeown M.J. Cognitive Profiles and Hub Vulnerability in Parkinson’s Disease. Frontiers in Neurology. 2018;9. DOI: 10.3389/fneur.2018.00482Lin S.-J., Baumeister, T.R., Garg S., McKeown M.J. Cognitive Profiles and Hub Vulnerability in Parkinson’s Disease. Frontiers in Neurology. 2018;9. DOI: 10.3389/fneur.2018.00482Broen M.P.G., Leentjens A.F.G., Hinkle J.T., Moonen A.J.H., Kuijf M.L., Fischer N.M.et al. Clinical markers of anxiety subtypes in Parkinson disease. Journal of Geriatric Psychiatry and Neurology. 2018;31(2):55–62. DOI: 10.1177/0891988718757369Broen M.P.G., Leentjens A.F.G., Hinkle J.T., Moonen A.J.H., Kuijf M.L., Fischer N.M. et al. Clinical markers of anxiety subtypes in Parkinson disease. Journal of Geriatric Psychiatry and Neurology. 2018;31(2):55–62. DOI: 10.1177/0891988718757369Bhattacharjee S. Impulse control disorders in Parkinson’s disease: Review of pathophysiology, epidemiology, clinical features, management, and future challenges. Neurology India. 2018;66(4):967. DOI: 10.4103/0028-3886.237019Bhattacharjee S. Impulse control disorders in Parkinson’s disease: Review of pathophysiology, epidemiology, clinical features, management, and future challenges. Neurology India. 2018;66(4):967. DOI: 10.4103/0028-3886.237019Buhmann C., Dogac S., Vettorazzi E., Hidding U., Gerloff C., & Jürgens T.P. The impact of Parkinson disease on patients’ sexuality and relationship. Journal of Neural Transmission. 2016;124(8):983–996. DOI: 10.1007/s00702-016-1649-8Buhmann C., Dogac S., Vettorazzi E., Hidding U., Gerloff C., & Jürgens T.P. The impact of Parkinson disease on patients’ sexuality and relationship. Journal of Neural Transmission. 2016;124(8):983–996. DOI: 10.1007/s00702-016-1649-8Heller J., Mirzazade S., Romanzetti S., Habel U., Derntl B., Freitag N.M. et al. Impact of gender and genetics on emotion processing in Parkinson’s disease — A multimodal study. NeuroImage: Clinical. 2018;18:305–314. DOI: 10.1016/j.nicl.2018.01.034Heller J., Mirzazade S., Romanzetti S., Habel U., Derntl B., Freitag N.M. et al. Impact of gender and genetics on emotion processing in Parkinson’s disease — A multimodal study. NeuroImage: Clinical. 2018;18:305–314. DOI: 10.1016/j.nicl.2018.01.034Zhou J., Zhang J., Li Y., Du L., Li Z., Lei F. et al. Gender differences in REM sleep behavior disorder: a clinical and polysomnographic study in China. Sleep Medicine. 2015;16(3):414–418. DOI: 10.1016/j.sleep.2014.10.020Zhou J., Zhang J., Li Y., Du L., Li Z., Lei F. et al. Gender differences in REM sleep behavior disorder: a clinical and polysomnographic study in China. Sleep Medicine. 2015;16(3):414–418. DOI: 10.1016/j.sleep.2014.10.020Haba-Rubio J., Frauscher B., Marques-Vidal P., Toriel J., Tobback N., Andries D.et al. Prevalence and determinants of rapid eye movement sleep behavior disorder in the general population. Sleep. 2017;41(2). DOI: 10.1093/sleep/zsx197Haba-Rubio J., Frauscher B., Marques-Vidal P., Toriel J., Tobback N., Andries D.et al. Prevalence and determinants of rapid eye movement sleep behavior disorder in the general population. Sleep. 2017;41(2). DOI: 10.1093/sleep/zsx197Ophey A., Eggers C., Dano R., Timmermann L., Kalbe E. Health-related quality of life subdomains in patients with Parkinson’s disease: the role of gender. Parkinson’s Disease. 2018:1–9. DOI: 10.1155/2018/6532320Ophey A., Eggers C., Dano R., Timmermann L., Kalbe E. Health-related quality of life subdomains in patients with Parkinson’s disease: the role of gender. Parkinson’s Disease. 2018:1–9. DOI: 10.1155/2018/6532320Balzer-Geldsetzer M., Klotsche J., Dodel R., Riedel O. Quality of life in a German cohort of Parkinson’s patients assessed with three different measures. Journal of Neurology. 2018;265(11):2713–2722. DOI: 10.1007/s00415-018-9047-9Balzer-Geldsetzer M., Klotsche J., Dodel R., Riedel O. Quality of life in a German cohort of Parkinson’s patients assessed with three different measures. Journal of Neurology. 2018;265(11):2713–2722. DOI: 10.1007/s00415-018-9047-9Buczak-Stec E.W., König H.-H., Hajek A. Impact of Incident Parkinson’s Disease on Satisfaction With Life. Frontiers in Neurology. 2018;9. DOI: 10.3389/fneur.2018.00589Buczak-Stec E.W., König H.-H., Hajek A. Impact of Incident Parkinson’s Disease on Satisfaction With Life. Frontiers in Neurology. 2018;9. DOI: 10.3389/fneur.2018.00589Heinzel S., Kasten M., Behnke S., Vollstedt E., Klein C., Hagenah J. et al. Age‐ and sex‐related heterogeneity in prodromal Parkinson’s disease. Movement Disorders. 2018;33(6):1025–1027. Portico. DOI: 10.1002/mds.27349Heinzel S., Kasten M., Behnke S., Vollstedt E., Klein C., Hagenah J. et al. Age‐ and sex‐related heterogeneity in prodromal Parkinson’s disease. Movement Disorders. 2018;33(6):1025–1027. Portico. DOI: 10.1002/mds.27349Savica R., Rocca W.A., Ahlskog J.E. When does Parkinson disease start? Archives of Neurology. 2010;67(7). DOI: 10.1001/archneurol.2010.135Savica R., Rocca W.A., Ahlskog J.E. When does Parkinson disease start? Archives of Neurology. 2010;67(7). DOI: 10.1001/archneurol.2010.135O’Reilly E.J., Gao X., Weisskopf M.G., Chen H., Schwarzschild M.A., Spiegelman D., Ascherio A. Plasma urate and Parkinson’s disease in women. American Journal of Epidemiology. 2010;172(6):666–670. DOI: 10.1093/aje/kwq195O’Reilly E.J., Gao X., Weisskopf M.G., Chen H., Schwarzschild M.A., Spiegelman D., Ascherio A. Plasma urate and Parkinson’s disease in women. American Journal of Epidemiology. 2010;172(6):666–670. DOI: 10.1093/aje/kwq195Cortese M., Riise T., Engeland A., Ascherio A., Bjørnevik K. Urate and the risk of Parkinson’s disease in men and women. Parkinsonism and Related Disorders. 2018;52:76–82. DOI: 10.1016/j.parkreldis.2018.03.026Cortese M., Riise T., Engeland A., Ascherio A., Bjørnevik K. Urate and the risk of Parkinson’s disease in men and women. Parkinsonism and Related Disorders. 2018;52:76–82. DOI: 10.1016/j.parkreldis.2018.03.026Lee Y., Park Y.-H., Lee J.J., Sohn Y.H., Lee J.-M., Lee P.H. Gender-specificeffect of uricacid on resting-state functional networks in de novo Parkinson’s disease. Parkinsonism and Related Disorders. 2018;52:49–54. DOI: 10.1016/j.parkreldis.2018.03.023Lee Y., Park Y.-H., Lee J.J., Sohn Y.H., Lee J.-M., Lee P.H. Gender-specific effect of uricacid on resting-state functional networks in de novo Parkinson’s disease. Parkinsonism and Related Disorders. 2018;52:49–54. DOI: 10.1016/j.parkreldis.2018.03.023Baksh R., Macklin E.A., Logan R., Zorlu M.M., Xia N., Crotty G.F. et al. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease. Annals of Neurology. 2019;85(4):593–599. Portico. DOI: 10.1002/ana.25436Baksh R., Macklin E.A., Logan R., Zorlu M.M., Xia N., Crotty G.F. et al. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease. Annals of Neurology. 2019;85(4):593–599. Portico. DOI: 10.1002/ana.25436Migdalska‐Richards A., Schapira, A.V. The relationship between glucocerebrosidase mutations and Parkinson disease. Journal of Neurochemistry. 2016;139(S1):77–90. Portico. DOI: 10.1111/jnc.13385Migdalska‐Richards A., Schapira, A.V. The relationship between glucocerebrosidase mutations and Parkinson disease. Journal of Neurochemistry. 2016;139(S1):77–90. Portico. DOI: 10.1111/jnc.13385Liu L., Xiong N., Zhang P., Chen C., Huang J., Zhang G. et al. Genetic variants in GAPDH confer susceptibility to sporadic Parkinson’s disease in a chinese han population. PLOS ONE. 2015;10(8):e0135425. DOI: 10.1371/journal.pone.0135425Liu L., Xiong N., Zhang P., Chen C., Huang J., Zhang G. et al. Genetic variants in GAPDH confer susceptibility to sporadic Parkinson’s disease in a chinese han population. PLOS ONE. 2015;10(8):e0135425. DOI: 10.1371/journal.pone.0135425Alcalay R.N., Wolf P., Levy O.A., Kang U.J., Waters C. et al. Alpha galactosidase A activity in Parkinson’s disease. Neurobiology of Disease. 2018;112, 85–90. DOI: 10.1016/j.nbd.2018.01.012Alcalay R.N., Wolf P., Levy O.A., Kang U.J., Waters C. et al. Alpha galactosidase A activity in Parkinson’s disease. Neurobiology of Disease. 2018;112, 85–90. DOI: 10.1016/j.nbd.2018.01.012Ping Z., Xiaomu W., Xufang, X., Wenfeng C., Liang S., Tao W. GAPDH rs1136666 SNP indicates a high risk of Parkinson’s disease. Neuroscience Letters. 2018;685:55–62. DOI: 10.1016/j.neulet.2018.06.011Ping Z., Xiaomu W., Xufang, X., Wenfeng C., Liang S., Tao W. GAPDH rs1136666 SNP indicates a high risk of Parkinson’s disease. Neuroscience Letters. 2018;685:55–62. DOI: 10.1016/j.neulet.2018.06.011Hemmerle A.M., Herman J.P., Seroogy K.B. Stress, depression and Parkinson’s disease. Experimental Neurology. 2012;233(1):79–86. DOI: 10.1016/j.expneurol.2011.09.035Hemmerle A.M., Herman J.P., Seroogy K.B. Stress, depression and Parkinson’s disease. Experimental Neurology. 2012;233(1):79–86. DOI: 10.1016/j.expneurol.2011.09.035Sieurin J., Andel R., Tillander A., Valdes E.G., Pedersen N.L., Wirdefeldt K. Occupational stress and risk for Parkinson’s disease: A nationwide cohort study. Movement Disorders. 2018;33(9):1456–1464. DOI: 10.1002/mds.27439Sieurin J., Andel R., Tillander A., Valdes E.G., Pedersen N.L., Wirdefeldt K. Occupational stress and risk for Parkinson’s disease: A nationwide cohort study. Movement Disorders. 2018;33(9):1456–1464. DOI: 10.1002/mds.27439Teschke K., Marion S.A., Tsui J.K.C., Shen H., Rugbjerg K., Harris M.A. Parkinson’s Disease and Occupation: Differences in Associations by Case Identification Method Suggest Referral Bias. American Journal of Industrial Medicine. 2013;57(2):163–171. DOI: 10.1002/ajim.22272Teschke K., Marion S.A., Tsui J.K.C., Shen H., Rugbjerg K., Harris M.A. Parkinson’s Disease and Occupation: Differences in Associations by Case Identification Method Suggest Referral Bias. American Journal of Industrial Medicine. 2013;57(2):163–171. DOI: 10.1002/ajim.22272Vlaar T., Kab S., Schwaab Y., Fréry N., Elbaz A., Moisan F. Association of Parkinson’s disease with industry sectors: a French nationwide incidence study. European Journal of Epidemiology. 2018;33(11):1101–1111. DOI: 10.1007/s10654-018-0399-3Vlaar T., Kab S., Schwaab Y., Fréry N., Elbaz A., Moisan F. Association of Parkinson’s disease with industry sectors: a French nationwide incidence study. European Journal of Epidemiology. 2018;33(11):1101–1111. DOI: 10.1007/s10654-018-0399-3Rozani V., Gurevich T., Giladi N., El‐Ad B., Tsamir J., Hemo B., Peretz C. Higher serum cholesterol and decreased Parkinson’s disease risk: A statin‐free cohort study. Movement Disorders. 2018;33(8):1298–1305. DOI: 10.1002/mds.27413Rozani V., Gurevich T., Giladi N., El‐Ad B., Tsamir J., Hemo B., Peretz C. Higher serum cholesterol and decreased Parkinson’s disease risk: A statin‐free cohort study. Movement Disorders. 2018;33(8):1298–1305. DOI: 10.1002/mds.27413Rafferty M.R., Schmidt P.N., Luo S. T., Li K., Marras C., Davis T.L. et al. Regular Exercise, Quality of Life, and Mobility in Parkinson’s Disease: A Longitudinal Analysis of National Parkinson Foundation Quality Improvement Initiative Data. Journal of Parkinson’s Disease. 2017;7(1):193–202. DOI: 10.3233/jpd-160912Rafferty M.R., Schmidt P.N., Luo S. T., Li K., Marras C., Davis T.L. et al. Regular Exercise, Quality of Life, and Mobility in Parkinson’s Disease: A Longitudinal Analysis of National Parkinson Foundation Quality Improvement Initiative Data. Journal of Parkinson’s Disease. 2017;7(1):193–202. DOI: 10.3233/jpd-160912Mantri S., Fullard M.E., Duda J.E., Morley J.F. Physical Activity in Early Parkinson Disease. Journal of Parkinson’s Disease. 2018;8(1):107–111. DOI: 10.3233/jpd-171218Mantri S., Fullard M.E., Duda J.E., Morley J.F. Physical Activity in Early Parkinson Disease. Journal of Parkinson’s Disease. 2018;8(1):107–111. DOI: 10.3233/jpd-171218Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz C.G. Levodopa‐induced dyskinesias. Movement Disorders. 2007;22(10):1379–1389. DOI: 10.1002/mds.21475Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz C.G. Levodopa‐induced dyskinesias. Movement Disorders. 2007;22(10):1379–1389. DOI: 10.1002/mds.21475Martinelli P., Contin M., Scaglione C., Riva R., Albani F., Baruzzi A. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? Neurological Sciences. 2003;24(3):192–193. DOI: 10.1007/s10072-003-0125-zMartinelli P., Contin M., Scaglione C., Riva R., Albani F., Baruzzi A. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? Neurological Sciences. 2003;24(3):192–193. DOI: 10.1007/s10072-003-0125-zGoudreau J.L., Maraganore D.M., Farrer M.J., Lesnick T.G., Singleton A.B., Bower J.H. et al. Case‐Control study of dopamine transporter‐1, monoamine oxidase‐B, and catechol‐O‐methyl transferase polymorphisms in Parkinson’s disease. Movement Disorders. 2002;17(6):1305–1311. DOI: 10.1002/mds.10268Goudreau J.L., Maraganore D.M., Farrer M.J., Lesnick T.G., Singleton A.B., Bower J.H. et al. Case‐Control study of dopamine transporter‐1, monoamine oxidase‐B, and catechol‐O‐methyl transferase polymorphisms in Parkinson’s disease. Movement Disorders. 2002;17(6):1305–1311. DOI: 10.1002/mds.10268Sampaio T.F., dos Santos E.U.D., de Lima G.D.C., dos Anjos R.S.G., da Silva R.C., Asano A.G.C. et al. MAO‐Band COMT genetic variations associated with levodopa treatment response in patients with Parkinson’s disease. The Journal of Clinical Pharmacology. 2018;58(7):920–926. DOI: 10.1002/jcph.1096Sampaio T.F., dos Santos E.U.D., de Lima G.D.C., dos Anjos R.S.G., da Silva R.C., Asano A.G.C. et al. MAO‐Band COMT genetic variations associated with levodopa treatment response in patients with Parkinson’s disease. The Journal of Clinical Pharmacology. 2018;58(7):920–926. DOI: 10.1002/jcph.1096Wang J., Liu Z.-L., Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology. 2001;56(12):1757–1759. DOI: 10.1212/wnl.56.12.1757Wang J., Liu Z.-L., Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology. 2001;56(12):1757–1759. DOI: 10.1212/wnl.56.12.1757Kaiser R., Hofer A., Grapengiesser A., Gasser T., Kupsch A., Roots I., Brockmö ller J. l-Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology. 2003;60(11):1750– 1755. DOI: 10.1212/01.wnl.0000068009.32067.a1Kaiser R., Hofer A., Grapengiesser A., Gasser T., Kupsch A., Roots I., Brockmö ller J. l-Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology. 2003;60(11):1750– 1755. DOI: 10.1212/01.wnl.0000068009.32067.a1dos Santos E.U.D., Sampaio T.F., Tenório dos Santos A.D., Bezerra Leite F.C., da Silva R.C., Crovella S. et al. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson’s disease. Journal of Pharmacy and Pharmacology. 2018;71(2):206–212. DOI: 10.1111/jphp.13031dos Santos E.U.D., Sampaio T.F., Tenório dos Santos A.D., Bezerra Leite F.C., da Silva R.C., Crovella S. et al. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson’s disease. Journal of Pharmacy and Pharmacology. 2018;71(2):206–212. DOI: 10.1111/jphp.13031Marras C., Austin P.C., Bronskill S.E., Diong C., Rochon P.A. Antipsychotic Drug Dispensing in Older Adults With Parkinsonism. The American Journal of Geriatric Psychiatry. 2018;26(12):1244–1257. DOI: 10.1016/j.jagp.2018.08.003Marras C., Austin P.C., Bronskill S.E., Diong C., Rochon P.A. Antipsychotic Drug Dispensing in Older Adults With Parkinsonism. The American Journal of Geriatric Psychiatry. 2018;26(12):1244–1257. DOI: 10.1016/j.jagp.2018.08.003Drummond N., McCleary L., Garcia L., McGilton K., Molnar F., Dalziel W. et al. Assessing determinants of perceived quality in transi tions for people with dementia: a prospective observational study. Canadian Geriatrics Journal. 2019;22(1):13–22. DOI: 10.5770/cgj.22.332Drummond N., McCleary L., Garcia L., McGilton K., Molnar F., Dalziel W. et al. Assessing determinants of perceived quality in transi tions for people with dementia: a prospective observational study. Canadian Geriatrics Journal. 2019;22(1):13–22. DOI: 10.5770/cgj.22.332Roediger J., Artusi C.A., Romagnolo A., Boyne P., Zibetti M., Lopiano L. et al. Effect of subthalamic deep brain stimulation on posture in Parkinson’s disease: A blind computerized analysis. Parkinsonism and Related Disorders. 2019;62:122–127. DOI: 10.1016/j.parkreldis.2019.01.003Roediger J., Artusi C.A., Romagnolo A., Boyne P., Zibetti M., Lopiano L. et al. Effect of subthalamic deep brain stimulation on posture in Parkinson’s disease: A blind computerized analysis. Parkinsonism and Related Disorders. 2019;62:122–127. DOI: 10.1016/j.parkreldis.2019.01.003Hariz G.-M., Limousin P., Zrinzo L., Tripoliti E., Aviles-Olmos I., Jahanshahi M., Hamberg K., Foltynie T. Gender differences in quality of life following subthalamic stimulation for Parkinson’s disease. Acta Neurologica Scandinavica. 2013;128(4):281–285. DOI: 10.1111/ane.12127Hariz G.-M., Limousin P., Zrinzo L., Tripoliti E., Aviles-Olmos I., Jahanshahi M., Hamberg K., Foltynie T. Gender differences in quality of life following subthalamic stimulation for Parkinson’s disease. Acta Neurologica Scandinavica. 2013;128(4):281–285. DOI: 10.1111/ane.12127Gatto N.M., Deapen D., Stoyanoff, S., PinderR., Narayan S., Bordelon Y., Ritz B. Lifetime exposure to estrogens and Parkinson’s disease in California teachers. Parkinsonism & Related Disorders. 2014;20(11):1149–1156. DOI: 10.1016/j.parkreldis.2014.08.003Gatto N.M., Deapen D., Stoyanoff, S., PinderR., Narayan S., Bordelon Y., Ritz B. Lifetime exposure to estrogens and Parkinson’s disease in California teachers. Parkinsonism & Related Disorders. 2014;20(11):1149–1156. DOI: 10.1016/j.parkreldis.2014.08.003Nicoletti A., Arabia G., Pugliese P., Nicoletti G., Torchia G., Condino F.et al. Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia. Clinical Neuropharmacology. 2007;30(5):276–280. DOI: 10.1097/wnf.0b013e318050c9f9Nicoletti A., Arabia G., Pugliese P., Nicoletti G., Torchia G., Condino F.et al. Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia. Clinical Neuropharmacology. 2007;30(5):276–280. DOI: 10.1097/wnf.0b013e318050c9f9Adams C., Kumar R. The effect of estrogen in a man with Parkinson’s disease and a review of its therapeutic potential. International Journal of Neuroscience. 2013;123(10):741–742. DOI: 10.3109/00207454.2013.797903Adams C., Kumar R. The effect of estrogen in a man with Parkinson’s disease and a review of its therapeutic potential. International Journal of Neuroscience. 2013;123(10):741–742. DOI: 10.3109/00207454.2013.797903Lobo R.A. Hormone-replacement therapy: current thinking. Nature Reviews Endocrinology. 2016;13(4):220–231. DOI: 10.1038/nrendo.2016.164Lobo R.A. Hormone-replacement therapy: current thinking. Nature Reviews Endocrinology. 2016;13(4):220–231. DOI: 10.1038/nrendo.2016.164Arnott J., Martinkovich S., Planey S.L., Shah D. Selective estrogen receptor modulators: tissue specificity and clinical utility. Clinical Interventions in Aging. 2014;9:1437. DOI: 10.2147/cia.s66690Arnott J., Martinkovich S., Planey S.L., Shah D. Selective estrogen receptor modulators: tissue specificity and clinical utility. Clinical Interventions in Aging. 2014;9:1437. DOI: 10.2147/cia.s66690Jacobsen D.E., Melis R.J.F., Verhaar H.J.J., Olde Rikkert M.G.M. Ralo xifene and Tibolone in Elderly Women: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial. Journal of the American Medical Directors Association. 2012;13(2):189.e1-189. e7. DOI: 10.1016/j.jamda.2011.05.005Jacobsen D.E., Melis R.J.F., Verhaar H.J.J., Olde Rikkert M.G.M. Ralo xifene and Tibolone in Elderly Women: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial. Journal of the American Medical Directors Association. 2012;13(2):189.e1-189. e7. DOI: 10.1016/j.jamda.2011.05.005Goekoop R., Barkhof F., Duschek E.J.J., Netelenbos C., Knol D.L., Scheltens P., Rombouts S.A. Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI Study in Healthy Elderly Males. Neuropsychopharmacology. 2005;31(7):1508–1518. DOI: 10.1038/sj.npp.1300956Goekoop R., Barkhof F., Duschek E.J.J., Netelenbos C., Knol D.L., Scheltens P., Rombouts S.A. Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI Study in Healthy Elderly Males. Neuropsychopharmacology. 2005;31(7):1508–1518. DOI: 10.1038/sj.npp.1300956Luchett S., Bossers K., Frajese G.V., Swaab D.F. Neurosteroid Biosynthetic Pathway Changes in Substantia Nigra and Caudate Nucleus in Parkinson’s Disease. Brain Pathology. 2010;20(5):945–951. Portico. DOI: 10.1111/j.1750-3639.2010.00396.xLuchett S., Bossers K., Frajese G.V., Swaab D.F. Neurosteroid Biosynthetic Pathway Changes in Substantia Nigra and Caudate Nucleus in Parkinson’s Disease. Brain Pathology. 2010;20(5):945–951. Portico. DOI: 10.1111/j.1750-3639.2010.00396.xPaba S., Frau R., C. Godar S., Devoto P., Marrosu F., Bortolato M. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders. Current Pharmaceutical Design. 2011;17(2):151–167. DOI: 10.2174/138161211795049589Paba S., Frau R., C. Godar S., Devoto P., Marrosu F., Bortolato M. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders. Current Pharmaceutical Design. 2011;17(2):151–167. DOI: 10.2174/138161211795049589Frau R., Savoia P., Fanni S., Fiorentini C., Fidalgo C., Tronci E.et al. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson’s disease. Experimental Neurology. 2017;291, 1–7. DOI: 10.1016/j.expneurol.2017.01.012Frau R., Savoia P., Fanni S., Fiorentini C., Fidalgo C., Tronci E.et al. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson’s disease. Experimental Neurology. 2017;291, 1–7. DOI: 10.1016/j.expneurol.2017.01.012Simunovic F., Yi M., Wang Y., Stephens R., Sonntag K.C. Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease. PLoS ONE. 2010;5(1):e8856. DOI: 10.1371/journal.pone.0008856Simunovic F., Yi M., Wang Y., Stephens R., Sonntag K.C. Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease. PLoS ONE. 2010;5(1):e8856. DOI: 10.1371/journal.pone.0008856Cullity E.R., Madsen H.B., Perry C.J., Kim J.H. Postnatal developmental trajectory of dopamine receptor 1 and 2 expression in cortical and striatal brain regions. Journal of Comparative Neurology. 2018;527(6):1039–1055. DOI: 10.1002/cne.24574Cullity E.R., Madsen H.B., Perry C.J., Kim J.H. Postnatal developmental trajectory of dopamine receptor 1 and 2 expression in cortical and striatal brain regions. Journal of Comparative Neurology. 2018;527(6):1039–1055. DOI: 10.1002/cne.24574Bispo J.M.M., Melo J.E.C., Gois A.M., Leal P.C., Lins,L.C.R.F., Souza M.F. et al. Sex differences in the progressive model of parkinsonism induced by reserpine in rats. Behavioural Brain Research. 2019;363, 23–29. DOI: 10.1016/j.bbr.2019.01.041Bispo J.M.M., Melo J.E.C., Gois A.M., Leal P.C., Lins,L.C.R.F., Souza M.F. et al. Sex differences in the progressive model of parkinsonism induced by reserpine in rats. Behavioural Brain Research. 2019;363, 23–29. DOI: 10.1016/j.bbr.2019.01.041Costa G., Porceddu P.F., Serra M., Casu M.A., Schiano V., Napolitano F. et al. Lack of Rhes Increases MDMA-induced neuroinflammation and dopamine neuron degeneration: role of gender and age. International Journal of Molecular Sciences. 2019;20(7):1556. DOI: 10.3390/ijms20071556Costa G., Porceddu P.F., Serra M., Casu M.A., Schiano V., Napolitano F. et al. Lack of Rhes Increases MDMA-induced neuroinflammation and dopamine neuron degeneration: role of gender and age. International Journal of Molecular Sciences. 2019;20(7):1556. DOI: 10.3390/ijms20071556Seyfried T.N., Choi H., Chevalier A., Hogan D., Akgoc Z., Schneider J.S. Sex-related abnormalities in substantia nigra lipids in Parkinson’s disease. ASN Neuro. 2018;10(1):175909141878188. DOI: 10.1177/1759091418781889Seyfried T.N., Choi H., Chevalier A., Hogan D., Akgoc Z., Schneider J.S. Sex-related abnormalities in substantia nigra lipids in Parkinson’s disease. ASN Neuro. 2018;10(1):175909141878188. DOI: 10.1177/1759091418781889Marin R., Diaz M. Estrogen interactions with lipid rafts related to neuroprotection. Impact of brain ageing and menopause. Frontiers in Neuroscience. 2018;12:128 DOI: 10.3389/fnins.2018.00128Marin R., Diaz M. Estrogen interactions with lipid rafts related to neuroprotection. Impact of brain ageing and menopause. Frontiers in Neuroscience. 2018;12:128 DOI: 10.3389/fnins.2018.00128Song Z., Yang H., Peckham E.M., Becker J.B. Estradiol-induced potentiation of dopamine release in dorsal striatum following amphetamine administration requires estradiol receptors and mGlu5. Eneuro. 2019;6(1):ENEURO.0446-18.2019. DOI: 10.1523/eneuro.0446-18.2019Song Z., Yang H., Peckham E.M., Becker J.B. Estradiol-induced potentiation of dopamine release in dorsal striatum following amphetamine administration requires estradiol receptors and mGlu5. Eneuro. 2019;6(1):ENEURO.0446-18.2019. DOI: 10.1523/eneuro.0446-18.2019Conway S.M., Puttick D., Russell S., Potter D., Roitman M.F., Chartoff E.H. Females are less sensitive than males to the motivational- and dopamine-suppressing effects of kappa opioid receptor activation. Neuropharmacology. 2019;146:231–241. DOI: 10.1016/j.neuropharm.2018.12.002Conway S.M., Puttick D., Russell S., Potter D., Roitman M.F., Chartoff E.H. Females are less sensitive than males to the motivational- and dopamine-suppressing effects of kappa opioid receptor activation. Neuropharmacology. 2019;146:231–241. DOI: 10.1016/j.neuropharm.2018.12.002Palmer A. L., Ousman, S. S. Astrocytes and aging. Frontiers in aging. Neuroscience. 2018;10:337. DOI: 10.3389/fnagi.2018.00337Palmer A. L., Ousman, S. S. Astrocytes and aging. Frontiers in aging. Neuroscience. 2018;10:337. DOI: 10.3389/fnagi.2018.00337Villa A., Gelosa P., Castiglioni L., Cimino M., Rizzi N., Pepe G. et al. Sex-specific features of microglia from adult mice. Cell Reports. 2018;23(12):3501–3511. DOI: 10.1016/j.celrep.2018.05.048Villa A., Gelosa P., Castiglioni L., Cimino M., Rizzi N., Pepe G. et al. Sex-specific features of microglia from adult mice. Cell Reports. 2018;23(12):3501–3511. DOI: 10.1016/j.celrep.2018.05.048Hanamsagar, R., Alter M.D., Block C.S., Sullivan H., Bolton J.L., Bilbo S.D. Generation of a microglial developmental index in mice and in humans reveals a sex difference in maturation and immune reactivity. Glia. 2017;65(9):1504–1520. Portico. DOI: 10.1002/glia.23176Hanamsagar, R., Alter M.D., Block C.S., Sullivan H., Bolton J.L., Bilbo S.D. Generation of a microglial developmental index in mice and in humans reveals a sex difference in maturation and immune reactivity. Glia. 2017;65(9):1504–1520. Portico. DOI: 10.1002/glia.23176Lenz K.M., Nugent B.M., Haliyur R., McCarthy M.M. Microglia Are Essential to Masculinization of Brain and Behavior. The Journal of Neuroscience. 2013;33(7):2761–2772. DOI: 10.1523/jneurosci.1268-12.2013Lenz K.M., Nugent B.M., Haliyur R., McCarthy M.M. Microglia Are Essential to Masculinization of Brain and Behavior. The Journal of Neuroscience. 2013;33(7):2761–2772. DOI: 10.1523/jneurosci.1268-12.2013Guan J., Yang B., Fan Y., Zhang J. GPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease. Neuroimmunomodulation. 2017:24(1):60–66. DOI: 10.1159/000478908Guan J., Yang B., Fan Y., Zhang J. GPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease. Neuroimmunomodulation. 2017:24(1):60–66. DOI: 10.1159/000478908Santos-Galindo M., Acaz-Fonseca E., Bellini M.J., Garcia-Segura L.M. Sex differences in the inflammatory response of primary astrocytes to lipopolysaccharide. Biology of Sex Differences. 2011;2(7). DOI: 10.1186/2042-6410-2-7Santos-Galindo M., Acaz-Fonseca E., Bellini M.J., Garcia-Segura L.M. Sex differences in the inflammatory response of primary astrocytes to lipopolysaccharide. Biology of Sex Differences. 2011;2(7). DOI: 10.1186/2042-6410-2-7Jaber S.M., Bordt E.A., Bhatt N.M., Lewis D.M., Gerecht S., Fiskum G., Polster B.M. Sex differences in the mitochondrial bioenergetics of astrocytes but not microglia at a physiologically relevant brain oxygen tension. Neurochemistry International. 2018;117, 82–90. DOI: 10.1016/j.neuint.2017.09.003Jaber S.M., Bordt E.A., Bhatt N.M., Lewis D.M., Gerecht S., Fiskum G., Polster B.M. Sex differences in the mitochondrial bioenergetics of astrocytes but not microglia at a physiologically relevant brain oxygen tension. Neurochemistry International. 2018;117, 82–90. DOI: 10.1016/j.neuint.2017.09.003Martin-Jiménez C., Gaitán-Vaca D.M., Areiza N., Echeverria V., Ashraf G.M., González J. et al. Astrocytes mediate protective actions of estrogenic compounds after traumatic brain injury. Neuroendocrinology. 2018;108(2):142–160. DOI: 10.1159/000495078Martin-Jiménez C., Gaitán-Vaca D.M., Areiza N., Echeverria V., Ashraf G.M., González J. et al. Astrocytes mediate protective actions of estrogenic compounds after traumatic brain injury. Neuroendocrinology. 2018;108(2):142–160. DOI: 10.1159/000495078Yun J., Yeo I.J., Hwang C.J., Choi D.-Y., Im H.-S., Kim J.Y. et al. Estrogen deficiency exacerbates Aβ-induced memory impairment through enhancement of neuroinflammation, amyloidogenesis and NF-ĸB activation in ovariectomized mice. Brain, Behavior, and Immunity. 2018;73:282–293. DOI: 10.1016/j.bbi.2018.05.013Yun J., Yeo I.J., Hwang C.J., Choi D.-Y., Im H.-S., Kim J.Y. et al. Estrogen deficiency exacerbates Aβ-induced memory impairment through enhancement of neuroinflammation, amyloidogenesis and NF-ĸB activation in ovariectomized mice. Brain, Behavior, and Immunity. 2018;73:282–293. DOI: 10.1016/j.bbi.2018.05.013Chamniansawat S., Sawatdiyaphanon C. Age-Related Memory Impairment Associated With Decreased Endogenous Estradiol in the Hippocampus of Female Rats. International Journal of Toxicology. 2018:37(3):207–215. DOI: 10.1177/1091581818761653Chamniansawat S., Sawatdiyaphanon C. Age-Related Memory Impairment Associated With Decreased Endogenous Estradiol in the Hippocampus of Female Rats. International Journal of Toxicology. 2018:37(3):207–215. DOI: 10.1177/1091581818761653

The authors declare that there are no conflicts of interest present.